Neurocrine Biosciences, Inc. (0K6R.L)
USD 104.65
(1.02%)
USD 104.65
(1.02%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 249.7 Million USD | 61.62% |
| 2022 | 154.5 Million USD | 72.43% |
| 2021 | 89.6 Million USD | -78.0% |
| 2020 | 407.3 Million USD | 1000.81% |
| 2019 | 37 Million USD | 75.26% |
| 2018 | 21.11 Million USD | 114.81% |
| 2017 | -142.54 Million USD | -1.03% |
| 2016 | -141.09 Million USD | -58.65% |
| 2015 | -88.92 Million USD | -46.89% |
| 2014 | -60.54 Million USD | -31.36% |
| 2013 | -46.09 Million USD | -1017.21% |
| 2012 | 5.02 Million USD | -86.63% |
| 2011 | 37.57 Million USD | 571.52% |
| 2010 | -7.96 Million USD | 84.39% |
| 2009 | -51.03 Million USD | 42.4% |
| 2008 | -88.61 Million USD | 57.25% |
| 2007 | -207.29 Million USD | -93.37% |
| 2006 | -107.2 Million USD | -383.1% |
| 2005 | -22.19 Million USD | 51.52% |
| 2004 | -45.77 Million USD | -51.29% |
| 2003 | -30.25 Million USD | 68.0% |
| 2002 | -94.53 Million USD | -156.13% |
| 2001 | -36.91 Million USD | -28.12% |
| 2000 | -28.8 Million USD | -71.48% |
| 1999 | -16.8 Million USD | 16.0% |
| 1998 | -20 Million USD | -492.16% |
| 1997 | 5.1 Million USD | -13.56% |
| 1996 | 5.9 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 129.8 Million USD | 99.69% |
| 2024 Q1 | 43.4 Million USD | -70.62% |
| 2024 Q2 | 65 Million USD | 49.77% |
| 2023 Q2 | 95.5 Million USD | 224.67% |
| 2023 FY | 249.7 Million USD | 61.62% |
| 2023 Q1 | -76.6 Million USD | -186.07% |
| 2023 Q4 | 147.7 Million USD | 77.74% |
| 2023 Q3 | 83.1 Million USD | -12.98% |
| 2022 Q1 | 13.9 Million USD | 290.41% |
| 2022 Q4 | 89 Million USD | 29.93% |
| 2022 Q3 | 68.5 Million USD | 505.33% |
| 2022 Q2 | -16.9 Million USD | -221.58% |
| 2022 FY | 154.5 Million USD | 72.43% |
| 2021 Q3 | 22.5 Million USD | -46.81% |
| 2021 Q4 | -7.3 Million USD | -132.44% |
| 2021 Q2 | 42.3 Million USD | 31.78% |
| 2021 FY | 89.6 Million USD | -78.0% |
| 2021 Q1 | 32.1 Million USD | -90.77% |
| 2020 Q2 | 79.6 Million USD | 112.83% |
| 2020 FY | 407.3 Million USD | 1000.81% |
| 2020 Q3 | -57.6 Million USD | -172.36% |
| 2020 Q4 | 347.9 Million USD | 703.99% |
| 2020 Q1 | 37.4 Million USD | 10.0% |
| 2019 FY | 37 Million USD | 75.26% |
| 2019 Q2 | 51.33 Million USD | 150.27% |
| 2019 Q3 | 53.78 Million USD | 4.77% |
| 2019 Q4 | 34 Million USD | -36.79% |
| 2019 Q1 | -102.11 Million USD | -664.86% |
| 2018 Q4 | 18.07 Million USD | -64.39% |
| 2018 Q2 | -5.91 Million USD | 85.86% |
| 2018 Q1 | -41.81 Million USD | -706.59% |
| 2018 FY | 21.11 Million USD | 114.81% |
| 2018 Q3 | 50.76 Million USD | 958.52% |
| 2017 Q1 | -78.32 Million USD | -75.39% |
| 2017 Q3 | -11.12 Million USD | 81.45% |
| 2017 FY | -142.54 Million USD | -1.03% |
| 2017 Q4 | 6.89 Million USD | 161.97% |
| 2017 Q2 | -59.98 Million USD | 23.42% |
| 2016 FY | -141.09 Million USD | -58.65% |
| 2016 Q2 | -40.28 Million USD | -109.09% |
| 2016 Q3 | -36.88 Million USD | 8.42% |
| 2016 Q4 | -44.65 Million USD | -21.07% |
| 2016 Q1 | -19.26 Million USD | 34.29% |
| 2015 Q2 | -23.98 Million USD | -1912.33% |
| 2015 Q3 | -34.43 Million USD | -43.56% |
| 2015 Q4 | -29.31 Million USD | 14.87% |
| 2015 Q1 | -1.19 Million USD | 93.87% |
| 2015 FY | -88.92 Million USD | -46.89% |
| 2014 Q3 | -15.87 Million USD | -18.64% |
| 2014 Q4 | -19.44 Million USD | -22.48% |
| 2014 Q2 | -13.38 Million USD | -13.0% |
| 2014 FY | -60.54 Million USD | -31.36% |
| 2014 Q1 | -11.84 Million USD | -11.28% |
| 2013 Q1 | -12.07 Million USD | -227.24% |
| 2013 FY | -46.09 Million USD | -1017.21% |
| 2013 Q4 | -10.64 Million USD | 4.39% |
| 2013 Q3 | -11.13 Million USD | 9.08% |
| 2013 Q2 | -12.24 Million USD | -1.38% |
| 2012 Q3 | -3.07 Million USD | -514.37% |
| 2012 Q4 | 9.49 Million USD | 408.32% |
| 2012 FY | 5.02 Million USD | -86.63% |
| 2012 Q1 | -886 Thousand USD | -166.57% |
| 2012 Q2 | -501 Thousand USD | 43.45% |
| 2011 Q2 | 1.97 Million USD | -31.44% |
| 2011 Q4 | 1.33 Million USD | -95.76% |
| 2011 FY | 37.57 Million USD | 571.52% |
| 2011 Q3 | 31.38 Million USD | 1488.16% |
| 2011 Q1 | 2.88 Million USD | 15.88% |
| 2010 Q3 | 3.33 Million USD | 164.69% |
| 2010 Q2 | -5.15 Million USD | 40.34% |
| 2010 Q1 | -8.63 Million USD | -9.1% |
| 2010 FY | -7.96 Million USD | 84.39% |
| 2010 Q4 | 2.48 Million USD | -25.38% |
| 2009 Q4 | -7.91 Million USD | 3.19% |
| 2009 Q3 | -8.17 Million USD | 46.49% |
| 2009 FY | -51.03 Million USD | 42.4% |
| 2009 Q1 | -19.66 Million USD | 31.85% |
| 2009 Q2 | -15.28 Million USD | 22.3% |
| 2008 Q1 | -21.07 Million USD | 83.53% |
| 2008 Q2 | -20.97 Million USD | 0.5% |
| 2008 Q3 | -17.71 Million USD | 15.55% |
| 2008 FY | -88.61 Million USD | 57.25% |
| 2008 Q4 | -28.85 Million USD | -62.92% |
| 2007 FY | -207.29 Million USD | -93.37% |
| 2007 Q4 | -127.97 Million USD | -369.81% |
| 2007 Q3 | -27.24 Million USD | -3.32% |
| 2007 Q2 | -26.36 Million USD | -2.5% |
| 2007 Q1 | -25.72 Million USD | -74.82% |
| 2006 Q4 | -14.71 Million USD | 62.41% |
| 2006 Q1 | -25.9 Million USD | -8.34% |
| 2006 FY | -107.2 Million USD | -383.1% |
| 2006 Q3 | -39.14 Million USD | -42.6% |
| 2006 Q2 | -27.44 Million USD | -5.98% |
| 2005 Q1 | -18.83 Million USD | 8.66% |
| 2005 FY | -22.19 Million USD | 51.52% |
| 2005 Q2 | -5.6 Million USD | 70.24% |
| 2005 Q3 | 26.15 Million USD | 566.65% |
| 2005 Q4 | -23.9 Million USD | -191.42% |
| 2004 Q4 | -20.61 Million USD | -1151.67% |
| 2004 Q3 | -1.64 Million USD | 85.2% |
| 2004 Q2 | -11.13 Million USD | 10.09% |
| 2004 Q1 | -12.38 Million USD | -487.72% |
| 2004 FY | -45.77 Million USD | -51.29% |
| 2003 FY | -30.25 Million USD | 68.0% |
| 2003 Q4 | 3.19 Million USD | 132.47% |
| 2003 Q3 | -9.83 Million USD | 3.82% |
| 2003 Q2 | -10.22 Million USD | 23.64% |
| 2003 Q1 | -13.39 Million USD | 65.48% |
| 2002 FY | -94.53 Million USD | -156.13% |
| 2002 Q4 | -38.78 Million USD | -91.69% |
| 2002 Q1 | -15.76 Million USD | -7.9% |
| 2002 Q2 | -19.75 Million USD | -25.29% |
| 2002 Q3 | -20.23 Million USD | -2.45% |
| 2001 Q4 | -14.61 Million USD | -682.77% |
| 2001 Q3 | 2.5 Million USD | 118.79% |
| 2001 Q2 | -13.34 Million USD | -16.41% |
| 2001 Q1 | -11.46 Million USD | -21.51% |
| 2001 FY | -36.91 Million USD | -28.12% |
| 2000 FY | -28.8 Million USD | -71.48% |
| 2000 Q1 | -6.04 Million USD | -63.43% |
| 2000 Q3 | -8.13 Million USD | -56.68% |
| 2000 Q4 | -9.43 Million USD | -15.97% |
| 2000 Q2 | -5.19 Million USD | 14.14% |
| 1999 FY | -16.8 Million USD | 16.0% |
| 1999 Q4 | -3.7 Million USD | 15.91% |
| 1999 Q2 | -4.6 Million USD | -12.2% |
| 1999 Q1 | -4.1 Million USD | 39.71% |
| 1999 Q3 | -4.4 Million USD | 4.35% |
| 1998 Q2 | -8 Million USD | -566.67% |
| 1998 Q3 | -4 Million USD | 50.0% |
| 1998 Q4 | -6.8 Million USD | -70.0% |
| 1998 FY | -20 Million USD | -492.16% |
| 1998 Q1 | -1.2 Million USD | 0.0% |
| 1997 Q4 | - USD | -100.0% |
| 1997 Q1 | 4.1 Million USD | -8.89% |
| 1997 FY | 5.1 Million USD | -13.56% |
| 1997 Q3 | 800 Thousand USD | 700.0% |
| 1997 Q2 | 100 Thousand USD | -97.56% |
| 1996 Q2 | 1.8 Million USD | 0.0% |
| 1996 FY | 5.9 Million USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 Q3 | -400 Thousand USD | -122.22% |
| 1996 Q4 | 4.5 Million USD | 1225.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Imunon, Inc. | -19.51 Million USD | 1379.53% |
| Homology Medicines, Inc. | -53.74 Million USD | 564.619% |
| uniQure N.V. | -308.47 Million USD | 180.946% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 560.803% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 382.207% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 170.92% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 264.727% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 190.43% |
| bluebird bio, Inc. | -211.91 Million USD | 217.831% |
| Blueprint Medicines Corporation | -506.98 Million USD | 149.252% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 310.694% |
| Adicet Bio, Inc. | -142.65 Million USD | 275.034% |
| Dynavax Technologies Corporation | -6.38 Million USD | 4008.28% |
| Editas Medicine, Inc. | -153.21 Million USD | 262.969% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 219.332% |
| Geron Corporation | -184.12 Million USD | 235.613% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 325.852% |
| Illumina, Inc. | -1.16 Billion USD | 121.507% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 156.234% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 81.613% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 68.343% |
| Myriad Genetics, Inc. | -112 Million USD | 322.946% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 146.588% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -18874.164% |
| Verastem, Inc. | -87.36 Million USD | 385.806% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 102.891% |
| Waters Corporation | 642.23 Million USD | 61.12% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 93.101% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 95.835% |
| Biogen Inc. | 1.16 Billion USD | 78.495% |
| Nektar Therapeutics | -276.05 Million USD | 190.453% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 390.704% |
| Perrigo Company plc | -12.7 Million USD | 2066.142% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 726.443% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 659.824% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -48.946% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 196.846% |
| Evolus, Inc. | -61.68 Million USD | 504.799% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 93.684% |
| FibroGen, Inc. | -284.23 Million USD | 187.851% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 79.863% |
| OPKO Health, Inc. | -188.86 Million USD | 232.212% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 156.719% |
| Exelixis, Inc. | 207.76 Million USD | -20.184% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 625.629% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 151.892% |
| Zoetis Inc. | 2.34 Billion USD | 89.347% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 204.373% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 691.72% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 168.171% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -135.255% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 11.326% |
| Insmed Incorporated | -749.56 Million USD | 133.313% |
| TG Therapeutics, Inc. | 12.67 Million USD | -1870.486% |
| Incyte Corporation | 597.59 Million USD | 58.216% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 132.834% |